On August 10, 2026, William Blair cut its Tenax Therapeutics Inc (TENX) rating from Outperform to Market Perform.
The past 90 days include five active firms, with one rating the stock bullish. As of October 30, 2026, 10 analysts place the consensus mean at $9.82, the median at $5.10 and the range at $4.04 to $36.75.
The Q4 FY2026 consensus calls for -$0.36 in EPS on $0 in revenue. The next earnings date is March 8, 2027.
